# A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Source: https://onco.cc/trials/nct04539496/  
OnCo record `nct04539496` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XZP-3287 and Fulvestrant in advanced solid tumours, run by Sihuan Pharmaceutical Holdings Group Ltd., active and no longer recruiting.

## Summary

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors is a phase 1/2 interventional study registered as NCT04539496 by Sihuan Pharmaceutical Holdings Group Ltd., with 402 participants enrolled, started 2018-05-22 and due to reach its primary completion in 2023-07-31. Interventions recorded: XZP-3287 and XZP-3287;Letrozole;Anastrozole;Fulvestrant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04539496
- Phase: 1/2
- Setting: A Multicenter, Open-label Phase I/II Study of XZP-3287 in Metastasis Solid Tumors in China
- Sponsor: Sihuan Pharmaceutical Holdings Group Ltd.
- Enrolled: 402

## Sources

- ClinicalTrials.gov NCT04539496: https://clinicaltrials.gov/study/NCT04539496

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [XZP-3287](https://onco.cc/drugs/xzp-3287/)

---
JSON: https://onco.cc/api/v1/entities/nct04539496.json